NVN Liquidation (DB:6LUA) - Aandelenkoers, Nieuws & Analyse

6LUA Overzicht aandelen

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Meer informatie

6LUA fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( €6K )

Negatief eigen vermogen

Aandelen zijn zeer illiquide

Heeft minder dan 1 jaar cash runway

+ 3 meer risico's

NVN Liquidation, Inc. Concurrenten

Real Brands

OTCPK:RLBD

US$2.7k

Bloomios

OTCPK:BLMS

US$6.8k

Avivagen

OTCPK:VIVX.F

US$7.8k

Black Bird Biotech

OTCPK:BBBT

US$3.7k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor NVN Liquidation
Historische aandelenkoersen
Huidige aandelenkoers	US$0.001
52 Week Hoogtepunt	US$1.97
52 Week Laag	US$0.001
Bèta	-0.24
11 maand verandering	0%
3 maanden verandering	-97.78%
1 Jaar Verandering	-99.92%
33 jaar verandering	-99.98%
5 jaar verandering	-99.99%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	6LUA	DE Pharmaceuticals	DE Markt
7D	0%	-1.2%	-0.02%
1Y	-99.9%	-20.1%	8.2%

Rendement versus industrie: 6LUA presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -20.1 % opleverde.

Rendement versus markt: 6LUA presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.2 % opleverde.

Prijsvolatiliteit

Is 6LUA's price volatile compared to industry and market?
6LUA volatility
6LUA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stabiele aandelenkoers: De aandelenkoers van 6LUA is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 6LUA in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	90	n/a	www.novan.com

NVN Liquidation, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van NVN Liquidation zich tot de beurswaarde?
6LUA fundamentele statistieken
Marktkapitalisatie	€5.14k
Inkomsten(TTM)	-€29.40m
Inkomsten(TTM)	€22.86m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is 6LUA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
6LUA resultatenrekening (TTM)
Inkomsten	US$24.92m
Kosten van inkomsten	US$24.45m
Brutowinst	US$473.00k
Overige uitgaven	US$32.52m
Inkomsten	-US$32.05m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.14
Brutomarge	1.90%
Nettowinstmarge	-128.61%
Schuld/Eigen Vermogen Verhouding	-1,164.1%

Hoe presteerde 6LUA op de lange termijn?

Bekijk historische prestaties en vergelijking

6LUA Overzicht aandelen

Risicoanalyse

NVN Liquidation, Inc. Concurrenten

OTCPK:RLBD

US$2.7k

OTCPK:BLMS

US$6.8k

OTCPK:VIVX.F

US$7.8k

OTCPK:BBBT

US$3.7k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.71 loss in 1Q 2022)

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.74 loss in FY 2021)

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

NVN Liquidation, Inc. Samenvatting

0.0x

0.0x

Inkomsten en omzet